BioStem Technologies (OTC: BSEM) Announces The Appointment Of Dr. Dave Woynarowski As Chief Medical Officer

OAKLAND PARK, FL--(Marketwired - Feb 1, 2016) - Dr. Dave Woynarowski was appointed Chief Medical Officer of Biostem Technologies, Inc. (OTC PINK: BSEM) effective immediately. Dr. Woynarowski received his medical degree from Temple University, and served as chief resident in his Internal Medicine Training program. He went on to become part of the resident education system, and twice receiving the prestigious Residents Teaching Award from his students and residents. He holds a Master's Degree in Physiology, and was a Certified Personal Trainer during his early medical career. He also served as Adjunct Professor to Hershey School of Medicine.

Dr. Woynarowski or more simply "Dr. Dave" as he is known to his patients has a background in Internal Medicine, and has been board certified in that discipline. He holds the A4M Anti-Aging medicine certification and was one of the first 30 physicians in the world to attain the AMA's certificate in Age Management Medicine. After practicing Internal Medicine for 15 years and Anti-Aging Medicine for 4 years he founded Dr. Dave's Best Nutraceuticals company in 2002 to fill the void in doctor designed nutraceuticals.

That company was acquired in November 2015 by Biostem Technologies, Inc. and Dr. Dave continues to direct its main functions including research and design.

Dr. Dave is also recognized as a worldwide expert on Telomeres and Telomerase. He has lectured on the topic multiple times to such groups as the A4M and AMMG.

In 2010 he wrote the first text book on Telomere biology for the non-scientist with co authors Dr. Mike Fossel and Greta Blackburn. Currently he is working on a second book which will include his expertise on other age related topics including stem cells and gene therapy.

On his transition to Biostem Technologies, Dr. Dave says, "This is actually a manifestation of a long term dream of mine. I have been working on developing a premier anti-aging team consisting of scientists, researchers, and entrepreneurs who are as dedicated to solving aging as I am. With that team now in place, I am excited to begin pursuing ideas that have been on hold for so long. We look forward to our ideas manifesting themselves into products and services that will help more people sooner!"

About Biostem Technologies, Inc. (BSEM):

Biostem Technologies (BSEM) is engaged in the advancement of regenerative medicine and anti-aging strategies throughout the United States, Europe, and Latin America. BSEM's goal is to deliver the highest standard wellness and stem cell products that are backed by science. Through scientific studies, we seek to become a world leader in the wellness arena. This will be accomplished by using the high quality nutraceuticals and stem cells. Our quest is to introduce the world, and our shareholders to our dedication to you and your well-being.

Mission Statement- Biostem Technologies is a Global Leader in Anti-Aging research. We are focused on advancing your quality of life, health span, and wellness.

Vision Statement- Biostem Technologies is a group of scientists, physicians, and visionaries creating the possibility of living life to its fullest. Our products and strategies are dedicated to helping you live your best, feel your best, and be your best.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.